Per Norlén
Chief Executive Officer bij WNTRESEARCH AB
Vermogen: - $ op 31-03-2024
Actieve functies van Per Norlén
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| WNTRESEARCH AB | Chief Executive Officer | 10-01-2024 | - |
| University of Lund | Corporate Officer/Principal | - | - |
Atlas Therapeutics AB
 Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Director/Board Member | - | - |
Loopbaan van Per Norlén
Eerdere bekende functies van Per Norlén
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EVAXION BIOTECH A/S | Chief Executive Officer | 03-10-2022 | 29-08-2023 |
| Chief Tech/Sci/R&D Officer | 01-03-2023 | 29-08-2023 | |
Targinta AB
 Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Chief Executive Officer | 01-09-2021 | 01-09-2022 |
| XINTELA AB | Chief Tech/Sci/R&D Officer | 01-07-2021 | 01-09-2022 |
| ALLIGATOR BIOSCIENCE AB | Chief Executive Officer | 01-07-2015 | 18-03-2021 |
| Chief Tech/Sci/R&D Officer | 01-09-2010 | 01-01-2018 | |
| A Bioscience Incentive AB | Director/Board Member | - | - |
| Chairman | - | - | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - | - |
Opleiding van Per Norlén
| University of Lund | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 9 |
| Denemarken | 2 |
Operationeel
| Chief Executive Officer | 4 |
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 7 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| WNTRESEARCH AB | Health Technology |
| XINTELA AB | Health Technology |
| EVAXION BIOTECH A/S | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Health Technology |
| A Bioscience Incentive AB | |
Targinta AB
Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022. | Health Technology |
- Beurs
- Insiders
- Per Norlén
- Ervaring
